Answers are grounded in this paper and cite their sources.
Nirsevimab protected against RSV single and coinfections, with no evidence of replacement of RSV with other respiratory viruses. Clinical Trials Registration. NCT03979313.
No takes yet. Share an insight, caveat, or question.
Arbetter et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: